Goodbody Health Inc. - Blood Testing Trial Success
RNS Number : 7952B
Goodbody Health Inc.
16 February 2022

16 February 2022

Goodbody Health Inc.
("Goodbody Health," or the "Company")


Blood testing trial success

Goodbody Health announces successful progress with blood testing.

Goodbody Health (AQSE: GDBY) is pleased to announce the rollout of its plan to introduce blood testing through its existing network of clinics while it continues to contract with more new pharmacies including 15 last week.


This process includes venous blood draws with an in-clinic phlebotomist and Goodbody has launched its own phlebotomy training academy, training up staff within its existing clinic network to allow them to offer in clinic health and wellness blood tests. Newly partnered clinics will also have the opportunity to train up to three members of their staff within the phlebotomy training school.


At the same time the Group continues to bring in innovative technologies into its clinics to offer results to tests such as cholesterol and diabetes delivered in minutes.


These tests help people assess their wellness and determine any lifestyle changes required to live better giving feedback to Goodbody Health to develop the model including additional products and services.


Meanwhile COVID testing revenues are still averaging at over 500 tests per day, remaining strong due to other country entry requirements although the UK restrictions have eased.


Geremy Thomas, Executive Chairman, said; "We have set up a model for blood testing, that our partners cannot wait to roll out as they see the benefits for everyone in their local areas, while continuing to provide PCR testing for our customer base."


For further information:

Marc Howells

Chief Executive Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255

Anne Tew

Chief Financial Officer

Goodbody Health Inc.

+44 (0) 20 7971 1255




AQSE Corporate Adviser

Arden Partners plc

Antonio Bossi / George Morgan

+ 44 (0) 20 7614 5900 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.